The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Open accessAbstract
BACKGROUND: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). METHODS: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint. RESULTS: Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874). CONCLUSIONS: Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The mTOR inhibitor sirolimus did not significantly change RFS in the SiLVER trial also, involving 525 patients with HCC undergoing liver transplantation91.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Self-citationGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“…prospective international phase III SiLVER trial failed to demonstrate an overall benefit of sirolimus in improving long-term recurrence-free survival beyond 5 years after LT, [256] the subgroup within Milan criteria had improved recurrence-free survival with mTOR inhibitor-based immunosuppression.”
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Metadata
- Authors
- Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., Wolf, P., Rostaing, L., Bechstein, W. O., Rizell, M., Powell, J., Hidalgo, E., Gugenheim, J., Wolters, H., Brockmann, J., Roy, A., Mutzbauer, I., Schlitt, A., Beckebaum, S., Graeb, C., Nadalin, S., Valente, U., Turrión, V. S., Jamieson, N., Scholz, T., Colledan, M., Fändrich, F., Becker, T., Söderdahl, G., Chazouillères, O., Mäkisalo, H., Pageaux, G.-P., Steininger, R., Soliman, T., de Jong, K. P., Pirenne, J., Margreiter, R., Pratschke, J., Pinna, A. D., Hauss, J., Schreiber, S., Strasser, S., Klempnauer, J., Troisi, R. I., Bhoori, S., Lerut, J., Bilbao, I., Klein, C. G., Königsrainer, A., Mirza, D. F., Otto, G., Mazzaferro, V., Neuhaus, P., & Schlitt, H. J.
- Affiliations
- University of Padua (IT)
- University Hospital Regensburg (DE)
- Université Paris-Est Créteil (FR)
- LMU Klinikum (DE)
- University Hospital Heidelberg (DE)
- Jena University Hospital (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University Hospital Frankfurt (DE)
- Corresponding author
- Geissler, Edward K.
- ORCID
- Geissler, Edward K.
- Schnitzbauer, Andreas A.
- Lamby, Philipp E.
- Duvoux, Christophe
- Burra, Patrizia
- Schmidt, Jan
- Settmacher, Utz
- Heise, Michael
- Rossi, Giorgio
- Cillo, Umberto
- Kneteman, Norman
- Adam, René
- Bachellier, Philippe
- Rostaing, Lionel
- Bechstein, Wolf O.
- Rizell, Magnus
- Powell, James
- Hidalgo, Ernest
- Gugenheim, Jean
- Wolters, Heiner
- Roy, André
- Graeb, Christian
- Nadalin, Silvio
- Valente, Umberto
- Colledan, Michele
- Becker, Thomas
- Söderdahl, Gunnar
- Chazouillères, Olivier
- Pageaux, Georges-Philippe
- Soliman, Thomas
- Pirenne, Jacques
- Pratschke, Johann
- Schreiber, Stefan
- Strasser, Simone
- Troisi, Roberto I.
- Bhoori, Sherrie
- Lerut, Jan
- Bilbao, Itxarone
- Königsrainer, Alfred
- Mirza, Darius F.
- Mazzaferro, Vincenzo
- Schlitt, Hans J.
- Venue
- Transplantation
- Published
- 2016-01
- Volume
- 100
- Issue
- 1
- Pages
- 116-125
- ISSN
- 0041-1337 (ISSN-L)
- PMC
- PMC4683033
- OpenAlex
- W2173253647
- Cited by
- 433
- References
- 39
- Citations by year
- 2026: 27 · 2025: 24 · 2024: 53 · 2023: 36 · 2022: 43 · 2021: 54 · 2020: 46 · 2019: 37 · 2018: 38 · 2017: 44 · 2016: 26
- FWCI
- 21.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Transplantation (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Pfizer
- Universitätsklinikum Regensburg
- Universität Regensburg
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- rapamycin, liver transplantation, hepatocellular carcinoma, mTOR inhibitors, immunosuppression, recurrence-free survival, overall survival, Milan criteria, patient selection, adverse events
- MeSH terms
- Adult, Age Factors, Aged, Australia, Canada, Drug Therapy, Combination, Europe, Female, Carcinoma, Hepatocellular, Humans, Immunosuppressive Agents, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Risk Factors, Time Factors, Liver Transplantation, Treatment Outcome, Disease Progression, Risk Assessment, Disease-Free Survival, Sirolimus, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. https://app.cochat.ai/papers/10.1097/tp.0000000000000965
- The paper
- Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., . . . Schlitt, H. J. (2016). Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. https://doi.org/10.1097/tp.0000000000000965
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.